ESR1 and breast carcinoma: Accounting for 10-17% of all breast carcinomas, triple-negative breast cancer (TNBC), which lacks the expression of estrogen receptor (ER), progesterone receptor (PR) and HER2, is the most aggressive subtype and is known for its poor prognosis and high recurrence probability [2].